Literature DB >> 19788606

Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.

Claire Z Larter1, Matthew M Yeh, Derrick M Van Rooyen, Narci C Teoh, John Brooling, Jing Yun Hou, Jacqueline Williams, Matthew Clyne, Christopher J Nolan, Geoffrey C Farrell.   

Abstract

BACKGROUND AND AIMS: We previously reported that steatohepatitis develops in obese, hypercholesterolemic, diabetic foz/foz mice fed a high-fat (HF) diet for 12 months. We now report earlier onset of steatohepatitis in relation to metabolic abnormalities, and clarify the roles of dietary fat and bodily lipid partitioning on steatosis severity, liver injury and inflammatory recruitment in this novel non-alcoholic steatohepatitis (NASH) model.
METHODS: Foz/foz (Alms1 mutant) and wild-type (WT) mice were fed a HF diet or chow, and metabolic characteristics and liver histology were studied at 2, 6, 12 and 24 weeks.
RESULTS: After 12 weeks HF-feeding, foz/foz mice were obese and diabetic with approximately 70% reduction in serum adiponectin. Hepatomegaly developed at this time, corresponding to a plateau in adipose expansion and increased adipose inflammation. Liver histology showed mild inflammation and hepatocyte ballooning as well as steatosis. By 24 weeks, HF-fed foz/foz mice developed severe steatohepatitis (marked steatosis, alanine aminotransferase elevation, ballooning, inflammation, fibrosis), whereas dietary and genetic controls showed only simple steatosis. While steatosis was associated with hepatic lipogenesis, indicated by increased fatty acid synthase activity, steatohepatitis was associated with significantly higher levels of CD36, indicating active fatty acid uptake, possibly under the influence of peroxisome proliferator-activated receptor-gamma.
CONCLUSION: In mice genetically predisposed to obesity and diabetes, HF feeding leads to restriction of adipose tissue for accommodation of excess energy, causing lipid partitioning into liver, and transformation of simple steatosis to fibrosing steatohepatitis. The way in which HF feeding 'saturates' adipose stores, decreases serum adiponectin and causes hepatic inflammation in steatohepatitis may provide clues to pathogenesis of NASH in metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788606     DOI: 10.1111/j.1440-1746.2009.05996.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

1.  Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?

Authors:  Gavin E Arteel
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.

Authors:  Derrick M Van Rooyen; Claire Z Larter; W Geoffrey Haigh; Matthew M Yeh; George Ioannou; Rahul Kuver; Sum P Lee; Narci C Teoh; Geoffrey C Farrell
Journal:  Gastroenterology       Date:  2011-06-23       Impact factor: 22.682

3.  Western Diet Promotes Renal Injury, Inflammation, and Fibrosis in a Murine Model of Alström Syndrome.

Authors:  Young Chul Kim; Souradipta Ganguly; Josselin Nespoux; Brent Freeman; Haiyan Zhang; David Brenner; Debanjan Dhar; Volker Vallon
Journal:  Nephron       Date:  2020-07-06       Impact factor: 2.847

Review 4.  Alström syndrome: insights into the pathogenesis of metabolic disorders.

Authors:  Dorothée Girard; Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-12-07       Impact factor: 43.330

5.  Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.

Authors:  Michiko Itoh; Takayoshi Suganami; Nobutaka Nakagawa; Miyako Tanaka; Yukio Yamamoto; Yasutomi Kamei; Shuji Terai; Isao Sakaida; Yoshihiro Ogawa
Journal:  Am J Pathol       Date:  2011-09-07       Impact factor: 4.307

6.  Low docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in China.

Authors:  Ju-Sheng Zheng; Amei Xu; Tao Huang; Xiaomei Yu; Duo Li
Journal:  Lipids       Date:  2012-04-19       Impact factor: 1.880

7.  Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.

Authors:  Fahrettin Haczeyni; Laurence Poekes; Hans Wang; Auvro R Mridha; Vanessa Barn; W Geoffrey Haigh; George N Ioannou; Matthew M Yeh; Isabelle A Leclercq; Narcissus C Teoh; Geoffrey C Farrell
Journal:  Obesity (Silver Spring)       Date:  2016-11-02       Impact factor: 5.002

8.  Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis.

Authors:  Priya Handa; Bryan D Maliken; James E Nelson; Vicki Morgan-Stevenson; Donald J Messner; Barjinderjit K Dhillon; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Clinton T Elfers; Christian L Roth; Kris V Kowdley
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

Review 9.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 10.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.